About Shire

We’re with you.

Longer than any other manufacturer, Shire* has been a reliable and consistent supplier of IgG treatment.1

Through Growth and Transition

Shire has the manufacturing expertise to confidently manage the challenges of developing complex therapies, including those created from donated human plasma which benefit from an end-to-end approach from securing donation to delivering treatment. Beginning with its 100 BioLife plasma donation centers, to its state-of-the-art fractionation and manufacturing facilities, Shire is working to optimize plasma-based manufacturing to meet the needs of current and emerging markets in ways that don’t exist today.1

To support the growing demand for plasma-derived therapies, Shire has invested more than $1 billion to build a new, state-of-the-art plasma fractionation facility in Covington, GA. This facility is expected to add up to 3 million liters of new capacity annually (30% increase) when fully functional. Shire also expects to continue expansion of its plasma collection network in Georgia and throughout the U.S.2,3

With Education and Support

Shire offers unprecedented support and a wealth of educational resources, created with the help of patients, caregivers, and healthcare professionals from the community. Support is offered without charge to patients and caregivers, regardless of treatment.


  1. Shire Annual Report 2017.
  2. Marketing Research Bureau. The plasma proteins market in the United States 2014. Published July 2015.
  3. BioLife Plasma Donation Centers. https://www.biolifeplasma.com/us/#/about-biolife/our-centers. Accessed February 13, 2018.

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.


Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.

© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17


Please expand for Indication and Detailed Important Safety Information.

Important Safety Information

What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.